Synnovation Therapeutics
Qipeng Fan has over 12 years of experience in Cancer Research, with a PhD in Molecular Genetics from China Agricultural University. QIPENG worked extensively on various research projects at Indiana University School of Medicine, focusing on areas such as Hedgehog and TGF-beta signaling in skin cancer, YAP signaling in ovarian cancer, and the role of FoxM1 or Zip4 in ovarian cancer. Qipeng held positions at Indiana University School of Medicine as a Research Associate and later as a Laboratory Operations Manager. Prior to that, they worked as a PostDoc at IUPUI. Currently, Qipeng is a Senior Research Investigator at Synnovation Therapeutics, starting in January 2022.
From 2005 to 2011, Qipeng Fan pursued a Doctor of Philosophy (Ph.D.) degree in Animal Molecular Genetics at the Chinese Agriculture University.
Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.